About
VeonGen is based on our passion to deliver gene therapy innovations and advances to people in need. Our proprietary science solves major limitations in current gene therapy approaches.
At VeonGen we are dedicated to developing innovative gene therapies to treat ophthalmic diseases with high unmet medical need, as well as partnering with leading biopharmaceutical players in other disease areas.
The company’s pipeline is built on three unique and proprietary adeno-associated virus (AAV) technology platforms. The first, vgAAV gene therapy vector platform, allows superior transduction efficiency and intravitreal, less invasive treatment administration. The second, REVeRT vector platform, targets diseases caused by mutations in large genes. The third allows bi-directional modulation of multiple genes.
VeonGen was founded in 2017 as a spin-off of the Ludwig-Maximilians-University (LMU) Munich. The company’s founding team includes highly experienced executives and internationally renowned experts with track records in developing retinal gene therapy programs from discovery to clinical stage.
Our core team
Scientific Advisory Board
We are proud to be supported by a distinguished and highly experienced Scientific Advisory Board of renowned experts in their individual fields.
Investors
In November 2019, we closed a series A financing round with two esteemed investors - WuXi AppTec and Sequoia Capital China known for investing in cutting-edge technologies and tomorrow’s treatments and cures for patients in need. The proceeds are enabling us to accelerate our proprietary viral vector-based gene therapy platforms and drive product development in two ophthalmic gene therapy programs.
About WuXi AppTec
WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps partners improve the productivity of advancing healthcare products through cost-effective and efficient solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec’s open-access platform is enabling more than 3,700 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that "every drug can be made and every disease can be treated."
About Sequoia Capital China
The Sequoia team helps daring founders build legendary companies. In partnering with Sequoia, companies benefit from the unmatched network and the lessons we've learned over 47 years. As “The Entrepreneurs Behind The Entrepreneurs”, leading venture capital firm Sequoia Capital China is renowned for investing early in many successful companies and focuses on four sectors: TMT, healthcare, consumer/service, and industrial technology.